Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm

Digestive Diseases and Sciences

Volumn 61, Issue 7, 2016, Pages 2132-2139

  Klair, Jagpal S ^a   Girotra, Mohit ^a   Hutchins, Laura F ^a   Caradine, Kari D ^b   Aduli, Farshad ^a   Garcia Saenz de Sicilia, Mauricio ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Colitis; Ipilimumab; Metastatic melanoma; Perforation

Indexed keywords

CREATININE; INFLIXIMAB; IPILIMUMAB; METHYLPREDNISOLONE; METRONIDAZOLE; PREDNISONE; VANCOMYCIN; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; AUTOIMMUNE COLITIS; AUTOIMMUNE DISEASE; BLOODY DIARRHEA; CANCER CHEMOTHERAPY; CASE REPORT; CASE STUDY; CECAL PERFORATION; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COLON BIOPSY; COLON ULCER; COLONOSCOPY; CREATININE BLOOD LEVEL; DESCENDING COLON; DIARRHEA; DRUG MEGADOSE; DRUG RECHALLENGE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUODENUM PERFORATION; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEMICOLECTOMY; HISTIOCYTE; HUMAN; ILEOSTOMY; INFLAMMATORY INFILTRATE; LAMINA PROPRIA; LARGE INTESTINE PERFORATION; LEUKOCYTOSIS; MALE; MELANOMA; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PEPTOCLOSTRIDIUM DIFFICILE; POSTOPERATIVE CARE; PRIORITY JOURNAL; SIGMOID; SIGMOIDOSCOPY; STEROID THERAPY; TREATMENT DURATION; VERY ELDERLY; WEAKNESS; CHEMICALLY INDUCED; GASTROINTESTINAL DISEASE;

AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLITIS; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; INFLIXIMAB; MALE; MELANOMA; MIDDLE AGED; PREDNISONE;

EID: 84957547203     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-016-4042-4     Document Type: Article

References (48)

1. Peggs KS, Quezada SA, Korman AJ, et al. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006;18:206–213.
2. Traynor K. Ipilimumab approved for metastatic melanoma. Am J Health Syst Pharm. 2011;68:768.
3. Highlights of prescribing information [YERVOYTM (ipilimumab)] [Internet] [updated 2011 Mar]. http://www.accessdata.fda.gov/ drugsatfda_docs/label/2011/125377s0000lbl.pdf. Accessed November 18, 2014.
4. Jochems C, Tucker JA, Tsang KY, et al. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother. 2014;63:407–418.
5. Kwon ED, Drake CG, Scher HI, et al. CA184-043 Investigators. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:700–712.
6. Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24:75–83.
7. van den Eertwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:509–517.
8. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691–2697.
9. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
10. Freeman HJ. Colitis associated with biological agents. World J Gastroenterol. 2012;18:1871–1874.
11. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711–723. Erratum in: N Engl J Med. 2010 Sep 23;363:1290.2.
12. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–2526.
13. Balch C, Buzaid A, Soong S, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–3648.
14. Ibrahim RA, Berman DM, DePril V, et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J Clin Oncol. 2011;29:8583.
15. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA. 2003;100:4712–4717.
16. Johnston RL, Lutzky J, Chodhry A, et al. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci. 2009;54:2538–2540.
17. Nancey S, Boschetti G, Cotte E, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3 + regulatory T cells: a mechanistic explanation for ipilimumab-induced severe enterocolitis? Inflamm Bowel Dis. 2012;18:E1598–E1600.
18. Lord JD, Hackman RC, Moklebust A, et al. Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3 + T cells. Dig Dis Sci. 2010;55:1396–1405.
19. Lee YH, Kim JH, Seo YH, Choi SJ, Ji JD, Song GG. CTLA-4 polymorphisms and susceptibility to inflammatory bowel disease: a meta-analysis. Hum Immunol. 2014;75:414–421.
20. Zhang M, Ni J, Xu WD, et al. Association of CTLA-4 variants with susceptibility to inflammatory bowel disease: a meta-analysis. Hum Immunol. 2014;75:227–233.
21. Chen Z, Zhou F, Huang S, et al. Association of cytotoxic T lymphocyte associated antigen-4 gene (rs60872763) polymorphism with Crohn’s disease and high levels of serum sCTLA-4 in Crohn’s disease. J Gastroenterol Hepatol. 2011;26:924–930.
22. Graziani G, Tentori L, Navarra P. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol Res. 2012;65:9–22.
23. Lebbe´ C, O’Day S, Chiarion Sileni V, et al. Analysis of the onset and resolution of immune related adverse events during treatment with ipilimumab in patients with metastatic melanoma. Presented at Perspectives in Melanoma XII, Scheveningen/the Hague, the Netherlands, October 2–4, 2008.
24. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24:2283–2289.
25. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155–164.
26. Sharma R, Gupta KL, Ammon RH, et al. Atypical presentation of colon perforation related to corticoid use. Geriatrics. 1997;52:88–90.
27. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007;12:864–872.
28. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti- CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007;13:1810–1815.
29. Weber J, Hamid O, Amin A, et al. Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun. 2013;13:7.
30. Oble DA, Mino-Kenudson M, Goldsmith J, et al. Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol. 2008;32:1130–1137.
31. Shahabi V, Berman D, Chasalow SD, et al. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. J Transl Med. 2013;11:75.
32. Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010;10:11.
33. Garcia-Varona A, Odze RD, Makrauer F. Lymphocytic colitis secondary to ipilimumab treatment. Inflamm Bowel Dis. 2013;19:E15–E16.
34. Mitchell KA, Kluger H, Sznol M, Hartman DJ. Ipilimumab-induced perforating colitis. J Clin Gastroenterol. 2013;47:781–785.
35. Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol. 2013;200:W468–W474.
36. Slangen RM, van den Eertwegh AJ, van Bodegraven AA, et al. Diarrhoea in a patient with metastatic melanoma: Ipilimumab ileocolitis treated with infliximab. World J Gastrointest Pharmacol Ther. 2013;4:80–82.
37. Pagès C, Gornet JM, Monsel G, et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res. 2013;23:227–230.
38. Andrews S, Holden R. Characteristics and management of immune related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res. 2012;4:299–307.
39. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723. Erratum in: N Engl J Med. 2010 Sep 23;363:1290.
40. O’Day S, Weber JS, Wolchok JD, et al. Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies. J Clin Oncol. 2011;29:abstr 8554.
41. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15:5591–5598.
42. Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti- CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm. 2009;24:321–325.
43. Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm. 2010;25:601–613.
44. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805–1811.
45. Pham T, Bachelez H, Berthelot JM, et al. TNF-alpha antagonist therapy and safety monitoring. Joint Bone Spine. 2011;78:15–185.
46. Kaya B, Aras O, Bat O, Bulut NE, Memisoglu K. Steroid-induced sigmoid diverticular perforation in a patient with temporal arteritis: a rare clinical pathology. Clin Med Insights Pathol. 2012;5:11–14.
47. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13:6681–6688.
48. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18:2039–2047.